Trends News Trends In Small Cell Lung Cancer Incidence And Survival

RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) delivers statistically significant and clinically meaningful improvement in overall survival benefit for Asian ...

SINGAPORE,First and only chemotherapy-free combination in the first-line setting to demonstrate an overall survival benefit versus osimertinib among Asian patients. Read More

Breaking Down Treatment Advancements for Small Cell Lung Cancer

Dr. Charles M. Rudin discussed recent treatment advancements for patients with small cell lung cancer. Read More

Imdelltra May Improve Survival in Small Cell Lung Cancer

Imdelltra significantly improves survival in SCLC patients post-platinum chemotherapy, meeting primary endpoints in the DeLLphi-304 trial. As a BiTE immunotherapy, Imdelltra enhances T cell-cancer ... Read More

Tarlatamab Improves Overall Survival in Small Cell Lung Cancer

Results showed tarlatamab demonstrated statistically significant and clinically meaningful improvement in overall survival vs standard of care therapy. Topline data were announced from a phase 3 trial ... Read More

Medicaid Expansion Tied to Improved Lung Cancer Survival

Medicaid expansion is associated with lower 2- and 4-year mortality among patients with resectable non-small cell lung cancer. Read More

Transformation of Lung Cancer; What the OR Team Had to Say; Microplastics and Cancer

News, features, and commentary about cancer-related issues ... Read More

Ivonescimab Plus Chemotherapy Demonstrates Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival in Patients with EGFR-Mutant Non-Small ...

MIAMI--(BUSINESS WIRE)--Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced topline results from the Phase III clinical trial, HARMONi, the first global Phase ... Read More

Tarlatamab in Small-Cell Lung Cancer after Platinum-Based Chemotherapy

Tarlatamab, a bispecific delta-like ligand 3–directed T-cell engager immunotherapy, received accelerated approval for the treatment of patients with previously treated small-cell lung cancer. Whether ... Read More

New Treatments and Trends in Lung Neuroendocrine Carcinomas

Neuroendocrine carcinomas (NECs), which include small-cell lung cancer (SCLC), are a highly heterogeneous group of aggressive cancers with poor prognosis, noted Martin Wermke, MD, of TU Dresden ... Read More

Lung cancer rising among non-smokers — here's why

Cigarette smoking is by far the biggest risk factor for lung cancer, data shows — but in a surprising turn of events, the most common form of the disease is primarily found in non-smokers. Researchers ... Read More

Characteristics and Associated Survival of Patients Diagnosed With Non–Small Cell Lung Cancer in a Designated Lung Cancer Program in Western Kenya

Two hundred forty-nine patients diagnosed with NSCLC were included with a median age at diagnosis of 61 (IQR, 52-70) years. Most patients were married (n = 177; 71%) and nonsmokers (n = 177; 71%) with ... Read More